GILD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

137.470

Open

136.850

VWAP

135.27

Vol

5.65M

Mkt Cap

166.63B

Low

134.100

Amount

763.91M

EV/EBITDA(TTM)

12.66

Total Shares

1.24B

EV

183.85B

EV/OCF(TTM)

18.35

P/S(TTM)

5.72

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Show More

Events Timeline

(ET)

2026-03-24

15:00:00

Clear Street Assigns Buy Rating to Cullinan Therapeutics with Price Target of $33

2026-03-24

07:10:00

Galapagos in Advanced Partnership Talks with Gilead

2026-03-23 (ET)

2026-03-23

18:20:00

Gilead Sciences Acquires Ouro Medicines

2026-03-23

18:20:00

Gilead Acquires Ouro Medicines for $1.675 Billion

2026-03-23

16:40:00

Trump Claims US-Iran Talks Boost Markets

2026-03-23

12:40:00

Gilead Sciences in Talks to Acquire Ouro Medicines for Up to $2B

2026-03-23

12:40:00

Gilead Nears Acquisition of Ouro Medicines for Up to $2B

2026-02-25 (ET)

2026-02-25

13:50:00

Gilead Sciences Presents New ARTISTRY-1 and ARTISTRY-2 Trial Data

News

CNBC

Entergy Partners with Meta, Stock Surges Over 8%

CNBC

AstraZeneca's Drug Trial Shows Promising Results

CNBC

Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment

Yahoo Finance

03-27Yahoo Finance

Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline

Yahoo Finance

03-25Yahoo Finance

Weave Bio Forms Strategic Advisory Board to Enhance AI in Regulatory Processes

NASDAQ.COM

03-24NASDAQ.COM

AVLV Stock Price Analysis and ETF Dynamics

19 Analyst Rating

Wall Street analysts forecast GILD stock price to rise

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Jefferies

Buy

initiated

$180

AI Analysis

2026-03-10

Reason

Jefferies

Price Target

$180

AI Analysis

2026-03-10

initiated

Buy

Reason

Jefferies initiated coverage of Gilead with a Buy rating and $180 price target. The firm calls Gilead "one of the best-positioned large-cap biotechs," citing the absence of a near-term intellectual property cliff, operating margins on the high end of its biotech/pharma peers and increasing operating leverage as the company builds scale across overlapping franchises.

Mizuho

Outperform

maintain

$140 -> $170

2026-02-19

Reason

Mizuho

Price Target

$140 -> $170

2026-02-19

maintain

Outperform

Reason

Mizuho raised the firm's price target on Gilead to $170 from $140 and keeps an Outperform rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Gilead Sciences Inc (GILD.O) is 14.44, compared to its 5-year average forward P/E of 11.81. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

11.81

Current PE

14.44

Overvalued PE

14.33

Undervalued PE

9.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

8.73

Current EV/EBITDA

9.78

Overvalued EV/EBITDA

9.91

Undervalued EV/EBITDA

7.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.75

Current PS

5.04

Overvalued PS

4.35

Undervalued PS

3.15

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stock should i buy right now

Intellectia · 61 candidates

Rsi Category: moderatePe Ttm: 10 - 30Return On Equity: >= 12.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Johnson & Johnson

579.15B

Micron Technology Inc

402.85B

Coca-Cola Co

325.87B

Cisco Systems Inc

315.68B

Merck & Co Inc

295.77B

Linde PLC

227.58B

Intellectia · 51 candidates

Market Cap: >= 30.00BPe Ttm: 8 - 25List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

JPMorgan Chase & Co

762.83B

Johnson & Johnson

579.15B

Procter & Gamble Co

333.48B

Coca-Cola Co

325.87B

Merck & Co Inc

295.77B

Morgan Stanley

251.50B

best stock buy right now

Intellectia · 23 candidates

Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDXOne Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Ball Corp

15.87B

FedEx Corp

83.40B

Merck & Co Inc

294.04B

Applied Materials Inc

268.68B

Snap-On Inc

18.84B

Eaton Corporation PLC

138.55B

What should i buy right now?

Intellectia · 57 candidates

Market Cap: >= 20.00BPe Ttm: 10 - 35List Exchange: XNYS, XNASReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Alphabet Inc

3.71T

Johnson & Johnson

571.52B

Micron Technology Inc

519.68B

Coca-Cola Co

326.99B

Caterpillar Inc

322.73B

Cisco Systems Inc

306.51B

Should I Buy any stock tomorrow

Intellectia · 47 candidates

Analyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 10.0%List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.38T

Alphabet Inc

3.71T

Eli Lilly and Co

867.39B

ASML Holding NV

522.31B

Micron Technology Inc

519.68B

Costco Wholesale Corp

434.74B

what stock should I buy today

Intellectia · 52 candidates

Pe Ttm: 12 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Johnson & Johnson

573.51B

Micron Technology Inc

519.64B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Linde PLC

228.94B

investment advice, stock recommendations.

Intellectia · 72 candidates

Dividend Yield Ttm: 1 - 4Price: $20.00 - $150.00Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 8 - 30Is Index Component: GSPC

Ticker

Name

Market Cap$

Bank of America Corp

339.31B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Abbott Laboratories

192.82B

Nextera Energy Inc

192.79B

cosa conviene comprare ora su plus500

Intellectia · 97 candidates

Market Cap: >= 10.00BBeta: LowRisk, ModerateRiskPe Ttm: 10 - 25Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Berkshire Hathaway Inc

1.06T

Exxon Mobil Corp

650.52B

Chevron Corp

392.73B

Coca-Cola Co

332.62B

Merck & Co Inc

285.83B

Goldman Sachs Group Inc

232.12B

list top stocks

Intellectia · 45 candidates

Market Cap: >= 50.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEReturn On Equity: >= 20.0%Is Index Component: GSPCMonthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.38T

Alphabet Inc

3.65T

Microsoft Corp

2.94T

Amazon.com Inc

2.23T

Meta Platforms Inc

1.55T

Broadcom Inc

1.53T

good shares to buy in US RIGHT NOW

Intellectia · 55 candidates

Market Cap: >= 10.00BPe Ttm: 10 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Johnson & Johnson

587.32B

Micron Technology Inc

453.70B

Coca-Cola Co

334.94B

Cisco Systems Inc

306.91B

Merck & Co Inc

289.49B

Linde PLC

221.47B

Whales Holding GILD

Pacific Investment Management Company LLC

Mubadala Investment Company PJSC

Middlefield Capital Corporation

Pacer Advisors, Inc.

Confluence Investment Management LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Gilead Sciences Inc (GILD) stock price today?

The current price of GILD is 134.25 USD — it has decreased -1.92

What is Gilead Sciences Inc (GILD)'s business?

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

What is the price predicton of GILD Stock?

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gilead Sciences Inc (GILD)'s revenue for the last quarter?

Gilead Sciences Inc revenue for the last quarter amounts to 7.92B USD, increased 4.70

What is Gilead Sciences Inc (GILD)'s earnings per share (EPS) for the last quarter?

Gilead Sciences Inc. EPS for the last quarter amounts to 1.74 USD, increased 25.18

How many employees does Gilead Sciences Inc (GILD). have?

Gilead Sciences Inc (GILD) has 17000 emplpoyees as of March 30 2026.

What is Gilead Sciences Inc (GILD) market cap?

Today GILD has the market capitalization of 166.63B USD.